Skip to main content
. 2014 Aug 21;8(5):2243–2248. doi: 10.3892/ol.2014.2472

Table II.

Tumor responses in the gemcitabine/docetaxel and pemetrexed/cisplatin groups.

Group No. patients CR PR SD PD
Gemcitabine/docetaxel 21 0 2 4 15
Pemetrexed/cisplatin 18 0 1 5 12

Patients were classified according to the Response Evaluation Criteria in Solid Tumors: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.